NZ586357A - Antibodies to the pcrv antigen of pseudomonas aeruginosa - Google Patents

Antibodies to the pcrv antigen of pseudomonas aeruginosa

Info

Publication number
NZ586357A
NZ586357A NZ586357A NZ58635708A NZ586357A NZ 586357 A NZ586357 A NZ 586357A NZ 586357 A NZ586357 A NZ 586357A NZ 58635708 A NZ58635708 A NZ 58635708A NZ 586357 A NZ586357 A NZ 586357A
Authority
NZ
New Zealand
Prior art keywords
sequence
pseudomonas aeruginosa
antibodies
pcrv
cdr3
Prior art date
Application number
NZ586357A
Other languages
English (en)
Inventor
Christopher R Bebbington
Kenneth Luehrsen
Geoffrey T Yarranton
Mark Baer
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of NZ586357A publication Critical patent/NZ586357A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ586357A 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa NZ586357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99167907P 2007-11-30 2007-11-30
PCT/US2008/085196 WO2009073631A2 (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
NZ586357A true NZ586357A (en) 2012-10-26

Family

ID=40527381

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586357A NZ586357A (en) 2007-11-30 2008-12-01 Antibodies to the pcrv antigen of pseudomonas aeruginosa

Country Status (15)

Country Link
US (3) US8044181B2 (enExample)
EP (1) EP2220117A2 (enExample)
JP (1) JP5781765B2 (enExample)
KR (1) KR20100097719A (enExample)
CN (1) CN101910197B (enExample)
AU (1) AU2008333985B2 (enExample)
BR (1) BRPI0819598A2 (enExample)
CA (1) CA2706732A1 (enExample)
EA (1) EA201000903A1 (enExample)
IL (1) IL206036A0 (enExample)
MX (1) MX2010005871A (enExample)
NZ (1) NZ586357A (enExample)
SG (1) SG186017A1 (enExample)
WO (1) WO2009073631A2 (enExample)
ZA (1) ZA201003852B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
EP2615172A1 (en) * 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) * 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR101259239B1 (ko) 2008-01-10 2013-04-29 시오노기세야쿠 가부시키가이샤 ＰｃｒＶ에 대한 항체
CA2751433A1 (en) * 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
PT2407537E (pt) * 2009-03-11 2015-02-17 Shionogi & Co Anticorpo pcrv humanizado com atividade anti-pseudomonal
JP2013515079A (ja) * 2009-12-22 2013-05-02 カロバイオス ファーマシューティカルズ インコーポレイティッド 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
KR102111171B1 (ko) * 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도
SMT202000542T1 (it) 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
JP6415987B2 (ja) 2012-03-02 2018-10-31 アブリンクス エン．ヴェー． シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
MX2017014002A (es) 2015-05-01 2018-08-01 Inhibrx Lp Moléculas de direccionamiento del sistema de secreción tipo iii .
HUE051896T2 (hu) 2015-07-16 2021-03-29 Inhibrx Inc Multivalens és multispecifikus DR5-kötõ fúziós fehérjék
CN110072554A (zh) * 2016-05-05 2019-07-30 宾夕法尼亚大学理事会 用于抗铜绿假单胞菌的dna抗体构建体
CA3108071A1 (en) * 2018-08-01 2020-02-06 Cephalon, Inc. Anti-cxcr2 antibodies and uses thereof
PH12021552903A1 (en) * 2019-06-11 2022-04-04 Regeneron Pharma Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
CN114072145B (zh) * 2020-06-01 2024-06-11 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225552A (en) * 1880-03-16 Disintegrating-mill
US108565A (en) * 1870-10-25 Improvement in snow-plows
US134098A (en) * 1872-12-17 Improvement in gage-cocks
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5219998A (en) * 1990-06-04 1993-06-15 Levin Robert H Yeast-derived epidermal growth factor
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
JP2000516452A (ja) 1996-07-16 2000-12-12 プリュックテュン，アンドレアス 可溶性が増大した免疫グロブリンスーパーファミリードメインおよびフラグメント
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
AU3580800A (en) * 1998-11-25 2000-06-26 Mcw Research Foundation, Inc. Method of and compositions for immunization with the (pseudomonas) v antigen
DE19918418C1 (de) * 1999-04-23 2000-10-19 Siegfried Mueller Pflanzvorrichtung mit Halterung
AU2001238677A1 (en) 2000-02-28 2001-09-12 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
JP4355786B2 (ja) * 2001-01-26 2009-11-04 エムシーダブリユー リサーチ フオンデーシヨン インコーポレーテツド シュードモナスｖ抗原を用いる免疫化のための方法および組成物
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1479695B1 (en) * 2003-05-14 2010-02-17 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005306502B2 (en) 2004-11-16 2012-11-15 Humanigen, Inc. Immunoglobulin variable region cassette exchange
CA2606576A1 (en) 2005-05-20 2006-11-23 Lonza Biologics Plc. High-level expression of recombinant antibody in a mammalian host cell
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20090317329A2 (en) 2005-07-05 2009-12-24 Baker Idi Heart & Diabetes Institute Holdings Limited Anticoagulation agent and uses thereof
CA2635445A1 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR101351208B1 (ko) 2006-06-21 2014-01-14 온코세라피 사이언스 가부시키가이샤 Ｆｚｄ10에 대한 종양-표적화 모노클로날 항체 및 이의 용도

Also Published As

Publication number Publication date
KR20100097719A (ko) 2010-09-03
EP2220117A2 (en) 2010-08-25
JP2011505381A (ja) 2011-02-24
US8044181B2 (en) 2011-10-25
CN101910197A (zh) 2010-12-08
IL206036A0 (en) 2010-11-30
AU2008333985B2 (en) 2015-02-05
US20120020986A1 (en) 2012-01-26
WO2009073631A3 (en) 2009-09-24
US8877191B2 (en) 2014-11-04
CN101910197B (zh) 2014-09-24
EA201000903A1 (ru) 2011-02-28
WO2009073631A2 (en) 2009-06-11
JP5781765B2 (ja) 2015-09-24
AU2008333985A1 (en) 2009-06-11
CA2706732A1 (en) 2009-06-11
SG186017A1 (en) 2012-12-28
MX2010005871A (es) 2010-06-09
US20090191186A1 (en) 2009-07-30
ZA201003852B (en) 2014-11-26
BRPI0819598A2 (pt) 2017-05-09
US20150030614A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
NZ586357A (en) Antibodies to the pcrv antigen of pseudomonas aeruginosa
MY200988A (en) CD3 Binding Antibodies
NZ712765A (en) Antibodies that bind csf1r
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ703035A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
NZ595235A (en) Compositions and methods for increasing muscle growth
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
NZ602294A (en) Monoclonal antibodies against c-met
NZ628923A (en) Targeted binding agents against b7-h1
AU2010234031A8 (en) Trivalent, bispecific antibodies
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
NZ607711A (en) Antibodies directed to her-3 and uses thereof
NZ602040A (en) Anti-lrp6 antibodies
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ626269A (en) Anti-phf-tau antibodies and their uses
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ605980A (en) Anti-fap antibodies and methods of use
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: KALOBIOS PHARMACEUTICALS, INC., US

Free format text: OLD OWNER(S): KALOBIOS PHARMACEUTICALS, INC.; KENNETH LUEHRSEN; GEOFFREY T. YARRANTON; CHRISTOPHER R. BEBBINGTON; MARK BAER

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 DEC 2015 BY CPA GLOBAL

Effective date: 20130313

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 DEC 2016 BY CPA GLOBAL

Effective date: 20151016

LAPS Patent lapsed